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Abstract
Background: Colonoscopy plays crucial role in the establishment of the diagnosis, management and follow-up of
ulcerative colitis (UC). None of the currently widely used endoscopic scores consider disease extent, and therefore
do not correlate with the real severity of UC. Our aim was to assess the accuracy of a new score, the Pancolonic
Modified Mayo Score that can reflect not only the severity, but the extent of active UC.
Methods: One hundred and four UC patients were enrolled in this prospective study. The Endoscopic Mayo Scores
of the involved area of the five colorectal segments were added; furthermore, the sum was multiplied by 3 in case
of eMayo ≥2 (range 0 [normal] to 45 [most severe]) to obtain the Pancolonic Modified Mayo Score (panMayo) in
order to clearly distinguish the active and inactive disease. We analysed the correlation of panMayo Score with eMayo
and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and complicated disease outcome. We compared the endoscopic
indices with serum and faecal inflammatory parameters and Riley Score.
Results: The panMayo Score correlated with eMayo and UCEIS. Every endoscopic score showed correlation with Riley Score,
CRP, haemoglobin, haematocrit, serum iron, faecal MMP-9 and calprotectin and also predicted a complicated disease
outcome. Only panMayo score correlated exclusively with the extent of UC.
Conclusions: We suggest that this new score gives additional information about disease extent besides disease activity
with a strong correlation with laboratory parameters of inflammation and with the other widely used endoscopic indices.
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Background
Ulcerative colitis (UC) is a chronic relapsing inflammatory
disease, therefore monitoring disease activity has a great
importance in optimising the therapy based on relevant
signs and symptoms. Several different scoring systems are
available to assess endoscopic disease activity in UC; how-
ever, multiple existing indices indicate the lack of an opti-
mal one. On the other hand, mucosal healing becomes
one of the desired therapeutic endpoints of inflammatory
bowel diseases nowadays [1]. Thus colonoscopy plays a
crucial role not only in the establishment of diagnosis, but
also in the management and therapeutic decision-making
of UC. An exact scoring system for the evaluation of the
mucosa is absolutely mandatory for the comparable,
standard care of patients with UC all over the world [2].
Truelove and Witts were the first who described a scor-
ing system to evaluate mucosal appearance as a measure
of activity for UC [3]. Several scoring indices have evolved
during the last decades. The most widely used ones are
the Mayo Score, and the validated [4] Ulcerative Colitis
Endoscopic Index of Severity (UCEIS) [1]. Both of these
scores assess vascular pattern, presence of erythema, fri-
ability, erosions, ulcerations and bleeding [5, 6]. Some
research confirmed that mucosal healing is associated with
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better disease outcome [7]. Histologic assessment and
scoring is therefore important for the evaluation of UC
activity predicting remission rates and risk of malignancy
or surgery. Currently, one of the most frequently used
histopathological scores is Riley Score [8]. Riley Score
incorporates the following histological features: (a) pres-
ence of acute inflammatory cell infiltrate (neutrophils in
the lamina propria), (b) crypt abscesses, (c) mucin deple-
tion, (d) surface epithelial integrity, (e) chronic inflamma-
tory cell infiltrate (round cells in the lamina propria), and
(f) crypt architectural irregularities [7, 8].
Based on a study from Japan, colonoscopy is preferred
over sigmoideoscopy for the evaluation of inflammation
in UC [9]. Disease extention has a significant implication
for prognosis due to the association between extensive
UC and colectomy and colorectal cancer; nevertheless,
disease localisation and extent determine treatment
choice, as well [10]. However, none of the currently
widely used endoscopic scores consider disease extent,
and therefore they do not correlate with the real severity
of UC outcome. Our aim was to assess the accuracy of a
new score (Pancolonic Modified Mayo Score) that as a
matter of fact is a modified Endoscopic Mayo Subscore
(eMayo) in order to reflect not only the activity, but the
extent of UC.
Methods
Study population
This single-centre, prospective study was carried out on
consecutive patients with confirmed diagnosis of UC
between January 2011 and October 2015. Diagnosis was
based on the European evidence-based Consensus on the
diagnosis and management of UC (ECCO) [11]. Disease
phenotype and extension were determined according to
the Montreal Classification [12] and based on the
affected anatomical segments (rectum, sigmoid colon,
descending, transverse and cecum/ascending colon).
Subjects with UC of varying disease activities and extent
were enrolled. Patients with Crohn’s disease or cases with
incomplete colonoscopy were excluded. One hundred
and four patients were included finally, who were exam-
ined by complete colonoscopy which performed by one
of three experienced endoscopists (T.M., Z.SZ. and F.N.)
in accordance with protocols. All patients had given their
written informed consent to the procedure. Observers,
who carried out the colonoscopy, rated mucosal lesions
(vascular pattern, granularity, friability, ulceration) and
the severity of inflammation for each segment and the
maximum extension of involvement. Thus, panMayo
Score, eMayo and UCEIS were determined in every pa-
tient. Biopsy specimens were taken from the most se-
verely affected area for histological examination and
scoring. Riley Score was determined for each patient by an
experienced gastropathologist.
Laboratory and faecal markers
We collected blood and faecal samples from every
patient to determine specific laboratory parameters for
inflammation, namely C-reactive protein (CRP), white
blood cell count (WBC), faecal calprotectin and matrix-
metalloproteinase (MMP)-9, in addition to haemoglobin,
haematocrit, thrombocytes and serum iron level. Faecal
MMP-9 concentrations were measured using ELISA
(Quantikine MMP9 assay, R&D System, UK). One gram
of the sample was diluted, homogenised and centrifuged
twice; the final supernatant was filtered and stored at
−20 °C until analysis that was in accordance with the
manufacturer’s instructions [13]. Faecal specimens were
stored at −20 °C, thawed and prepared for a calprotectin
quantitative lateral flow assay as described by the manufac-
turer (Quantum Blue, Bühlmann Labortories, Switzerland).
Pancolonic modified Mayo score
Pancolonic Modified Mayo Score (panMayo) was calculated
with the combination of disease extension and severity
(Table 1). The eMayo Score of the five colorectal segments
(ascendending, transverse, descendending, sigmoid colon
and rectum) was determined separately and added after-
wards. Finally, the sum was multiplied by the Inflammatory
Constant if eMayo was ≥2 at least in one segment to clearly
distinguish between the active and inactive disease. Inflam-
matory constant (IC = 3) was defined at the beginning of
the study as the smallest number that can equilibrate the
difference between the sum of the inactive and active cases
Table 1 Calculation of panMayo score
Involvement (points)
eMayo (points) 1 2 3 4 5
0 0 0 0 0 0
1 1 2 3 4 5
2 2 × 3 = 6 4 × 3 = 12 6 × 3 = 18 8 × 3 = 24 10 × 3 = 30
3 3 × 3 = 9 6 × 3 = 18 9 × 3 = 27 12 × 3 = 36 15 × 3 = 45
Explanation:
Involvement: rectum: 1 point, rectum-sigmoid: 2 points, descending colon: 3 points, transverse colon: 4 points, cecum/ascending colon: 5 points
If no Inflammation (eMayo 0–1 points): eMayo points x involvement [1–5]
If active inflammation is presented in any segment: eMayo points x involvement [1–5] × 3
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resulting a broad range from 0 [normal] to 45 [most severe,
pancolitis with eMayo 3 in each segment]). Inclusion of IC
is important, because calculation without IC results the
same points in some cases, thus it would be impossible to
distinguish different extent and activity by panMayo Score.
The most important unmet need for widely used scoring
systems in clinical practice that the score simultaneously re-
flect on the severity and the extension of the disease. The
aim of panMayo score was to compensate this gap. If you
heard that the eMayo score is 3 points, you do not know
that what is the extension of disease and what is therefore
exactly the clinical severity of the disease. In contrary, pan-
Mayo Score includes both parameters, for example pan-
Mayo 45 points is a pancolitis with severe inflammation in
all segments.
We analysed the correlation of panMayo Score with the
endoscopic indices and the complicated disease outcome.
The panMayo Score was compared with Endoscopic Mayo
Score and UCEIS to assess the utility of our new score.
Complicated disease outcome was defined as the need of
hospitalization and/or colectomy during the follow-up.
Statistical analysis
Correlation of the panMayo Score with clinical, endoscopic
and histological indices (partial Mayo Subscore, eMayo
Subscore, UCEIS, Riley Score), laboratory measures of
disease activity and anaemia (C-reactive protein, faecal cal-
protectin, faecal MMP-9, serum iron, haemoglobin, haem-
atocrit etc.) were estimated using the multiple correlation
analysis with Spearman method. Logrank test was used to
determine connection between assessed scores and hospi-
talisation/colectomy rates. Receiver operating characteristic
(ROC) curve analysis was performed to determine the pre-
dictive power of the panMayo Score level. Area under ROC
curve (AUC), confidence interval for AUC, sensitivity and
specificity were calculated. The cut-off level was deter-
mined by the maximum value of Youden’s index (sensitiv-
ity + specificity-1). The statistical analysis was performed
using R (version 3.2.0) statistical software. P < 0.05 was con-
sidered as statistically significant.
Results
Patient characteristics
Out of 104 outpatients, 58 were female and 46 were
male; the mean age at enrolment was 43.9 ± 14.7 years.
The mean duration of the disease was 8.3 ± 0.7 years.
Left-sided colitis was the most common extent (Table 2).
On the basis of Mayo Score, 18 patients were in remis-
sion, 33 showed mild, 30 moderate and 8 severe disease
activity. Nine patients did not require any treatment;
however, 65 patients were on 5-ASA, 39 on corticoster-
oid, 37 on thiopurine, 15 on infliximab and one on
cyclosporine-A therapy. Thirty-nine patients were also
treated with topically administered drugs. Mean CRP
was 21.7 ± 41.4 mg/l, and faecal calprotectin and MMP-
9 were also elevated (632.8 ± 874.8 μg/g; 6.8 ± 8.3 ng/l)
in the enrolled patients. Strong correlation was shown
between the inflammatory markers and the assessed
endoscopic scores (see below). Serum and faecal param-
eters of enrolled patients are presented in Table 3. The
mean duration of patient follow-up was 20.7 months
(range, 0.3–54.5 months). During the follow-up period,
21 patients required hospitalisation due to relapse
(mean: 0.7 times; range 0–15 times) and in 18 cases
because of other causes not related to UC (mean: 0.2
Table 2 Characteristics of enrolled patients
No. of enrolled patients 104
Male/female 46/58
Mean age (±SD, years) 43.9 (±14.7)
Mean age at diagnosis(±SD, years) 35.3 (±14.7)
Mean disease duration (±SD, years) 8.3 ± 0.7
Localisation of disease:
Rectum 23
Sigmoid colon 28
Descending colon 18
Transverse colon 12
Ascending colon (±cecum) 23
Disease activity
The mean of eMayo Score (mean ± SD, points) 1.8 ± 1.2
The mean of UCEIS (mean ± SD, points) 6.3 ± 2.4
The mean of panMayo Score (mean ± SD, points) 14.2 ± 13.7
Therapy:
5-ASA 65
Corticosteroids 39
Thiopurines 37
Cyclosporine-A 1
Biological therapy: infliximab 15
Topical 39
No treatment 9
Table 3 Laboratory markers of enrolled patients
Laboratory parameter value
CRP (mean ± SD, mg/l) 21.7 ± 41.4
WBC (mean ± SD, G/l) 7.8 ± 3.3
Thrombocytes (mean ± SD, G/l) 299.3 ± 99.9
Haematocrit (mean ± SD, %) 39.1 ± 5.1
Haemoglobin (mean ± SD, g/l) 130.6 ± 19.7
Serum iron (mean ± SD, umol/l) 12.3 ± 6.2
Faecal calprotectin (mean ± SD, μg/g) 632.8 ± 874.8
Faecal MMP-9 (mean ± SD, ng/ml 6.8 ± 8.3
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times; range: 0–3 times). Nine of 104 subjects under-
went colectomy during this period.
Comparison between indices
PanMayo score
The mean panMayo Score was 14.2 ± 13.7 points (range,
0–45 points). Inactive and active disease was demon-
strated in 45 and 59 patients. The ROC analysis revealed
an AUC of 0.884 (p < 0.001, 95% CI: 0,822–0,946). The
sensitivity and specificity of panMayo in the establish-
ment of disease activity was 100% and 69.2%.
This new score correlated significantly with disease
extent (R = 0.3; p < 0.001) and partial Mayo Score (R =
0.7; p < 0.001). In addition, it showed a strong associ-
ation with the histological assessment, namely Riley
Score (R = 0.7; p < 0.001). We found panMayo Score to
correlate with CRP (R = 0.5; p < 0.001), faecal MMP-9
(R = 0.5; p < 0.001), calprotectin (R = 0.35; p < 0.043),
leucocyte (R = 0.3; p = 0.009), thrombocyte levels (R =
0.3; p = 0.003), and also with haemoglobin (R = −0.3;
p = 0.001), haematocrit (R = −0.3; p = 0.004) and serum
iron level (R = −0.5; p < 0.001) (Table 4). Significant associ-
ation was shown between panMayo Score and hospitalisa-
tion rate (p = 0.043). After reviewing our data, we observed
a relationship between panMayo Score as a linear variable
and colectomies, although this could not be substantiated
by statistical analysis (p = 0.6) (Fig. 1).
Endoscopic Mayo score
The mean eMayo Score was 1.8 ± 1.2 points (range, 0–3
points) in this study. Inactive and active disease was presented
in 41 and 63 patients. eMayo Subscore showed high correl-
ation with partial Mayo Score (R= 0.7; p < 0.001), Riley Score
(R= 0.7; p < 0.001), CRP (R= 0.3; p= 0.004) and faecal MMP-
9 (R= 0.5; p < 0.001), but also with faecal calprotectin (R=
0.4; p= 0.019), serum iron (R=−0.4; p= 0.004) and leucocyte
level (R= 0.3; p= 0.007), haemoglobin (R=−0.3; p= 0.02) and
haematocrit (R=−0.2; p = 0.02). We did not find association
with disease extent (R=−0.04; p= 0.7) and thrombocytes (R
= 0.2; p= 0.1) (Table 4). We found that eMayo is strongly
connected with hospitalisation (p= 0.028) and colectomy
rates (p= 0.008).
UCEIS
The mean UCEIS was 6.3 ± 2.4 points (range, 3–11
points). Inactive and active disease was shown in 41
and 63 patients. UCEIS correlated with partial Mayo
Score (R = 0.7; p < 0.001), Riley Score (R = 0.7; p < 0.001), fae-
cal MMP-9 (R = 0.5; p < 0.001), faecal calprotectin (R= 0.35;
p= 0.043), CRP (R= 0.5; p < 0.001), leucocyte count (R = 0.3;
p= 0.009), thrombocytes (R = 0.3; p= 0.003), haemoglobin
(R =−0.3; p= 0.001), haematocrit (R =−0.3; p = 0.004), and
serum iron level (R=−0.5; p < 0.001), but not with disease
extent (R =−0.04; p = 0.7) (Table 4). UCEIS showed a signifi-
cant connection with hospitalisations (p < 0.001) and colecto-
mies (p < 0.001).
Correlation between indices
The panMayo Score correlated with eMayo (R = 0.853;
p < 0.001) and UCEIS (R = 0.783; p < 0.001), and eMayo
with UCEIS as well (R = 0.932; p < 0.001).
Discussion
In this study we assessed the diagnostic value of a new,
modified endoscopic score. The panMayo Score revealed a
significant correlation with laboratory parameters of inflam-
mation and anaemia, disease extension and histological activ-
ity of UC. Furthermore, despite the modification it showed
100% sensitivity with the “mother” endoscopic disease activ-
ity eMayo Score.
Use of endoscopic scoring systems is recommended for
the evaluation of the prognosis and efficacy of treatment.
The ideal score would be easy to use, reproducible, reli-
able, responsive to changes and validated [14]. Several
endoscopic scoring systems are available for the assess-
ment of disease severity, although only UCEIS and ulcera-
tive colitis colonoscopic index of severity (UCCIS) [15]
received formal validation [16]. UCEIS with a total score
of 3 to 11 (or modified: 0–8) points was created based on
vascular pattern, bleeding, and erosion/ulceration [17].
The study of Corte et al. showed that UCEIS has a predict-
ive value also, because it was associated with the outcome
of acute severe UC [18]. The Mayo Score takes into
account four variables; these are stool frequency, rectal
bleeding, the physician’s global assessments and findings
at endoscopy, namely the eMayo Score [17]. eMayo Score
differentiates between endoscopically inactive, mild, mod-
erate and severe disease. Every endoscopic score indicates
the severity of inflammation, but not the extent of the
Table 4 Correlation between assessed endoscopic scores and
clinical/laboratory markers
eMayo UCEIS panMayo
Spearman
coefficient
(R)
p Spearman
coefficient
(R)
p Spearman
coefficient
(R)
p
Disease
extension
−0,04 0,687 −0,078 0,429 0,339 <0.001
partial Mayo
Score
0,714 <0.001 0,714 <0.001 0,692 <0.001
CRP 0,306 0,004 0,481 <0.001 0,481 <0.001
Leukocytes 0,283 0,007 0,276 0,009 0,278 0,009
Haematocrit −0,237 0,025 −0,3 0,004 −0,3 0,004
Haemoglobin −0,238 0,024 −0,337 0,001 −0,337 0,001
Thrombocytes 0,175 0,102 0,307 0,003 0,307 0,003
Serum Iron −0,352 0,001 −0,499 <0.001 −0,499 <0.001
Riley Score 0,724 <0.001 0,691 <0.001 0,691 <0.001
Calprotectin 0,399 0,019 0,349 0,043 0,349 0,043
MMP-9 0,505 <0.001 0,554 <0.001 0,554 <0.001
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inflamed colon which is a critically important detail for
the optimisation of the therapy [10, 19]. The panMayo
Score describes the bowel mucosa similarly to eMayo, but
it also includes disease extent. We found strong correl-
ation between panMayo Score and UCEIS, and eMayo as
well. In addition, panMayo showed significant association
with serum and faecal inflammatory markers. Therefore,
this new score can correctly demonstrate the activity of
UC and revealed unique correlation with disease extent
hereby indicating one of the significant factors of disease
outcome. Patients with initial diagnosis of pancolitis tend
to present with more frequent complications, extraintesti-
nal manifestations, occurrence of colorectal cancer is
higher among them, and they are more likely to require
immunosuppressive or surgical therapy [20, 21].
Despite general principles that treatment decisions
should be based on disease activity, pattern of the disease
and its distribution, colonoscopy and its evaluation may
also play a crucial role in the therapy [19]. The panMayo
Score correlates with inflammatory markers, and with
parameters of anaemia as well, that is the most common
systemic complication or extraintestinal manifestation of
UC [22]. Anaemia is a disease activity related condition
(triggered by blood loss and inflammation) in UC, more-
over sometimes it is the only sign of an ongoing
inflammation [23]. Furthermore, in another study, an-
aemia was shown to be more common in patients with
UC requiring immunosuppressive therapy [24]. Neverthe-
less, anaemia in a population-based IBD cohort was asso-
ciated with the extent of UC [25] and in our previous
study the need for blood transfusion was a significant pre-
dictor of a subsequent colectomy [26]. It should be noted
that disease location and extension has a great influence
on the prognosis: approximately one third of patients with
extensive UC will require colectomy during the disease
course [27]. Nine of our patients had colectomy during
the follow-up period. The panMayo Score as well as
eMayo Score, and UCEIS have a predictable value on out-
come in our study (Fig. 1).
To improve the accuracy of the endoscopic Mayo score,
another work group had also created an alteration on the
eMayo Score. The Modified Endoscopic Mayo Score
which, similarly to the panMayo Score, considers the dis-
tribution of UC, showed good correlation with clinical,
biological and histological activity of UC. However, calcu-
lation seems to be slightly difficult: after counting Modi-
fied Score and Extended Modified Score, the Modified
Mayo Endoscopic Score [28] was obtained by dividing the
Extended Modified Score with the number of segments
with active inflammation.
Fig. 1 Logrank analysis of hopitalisation free survival shown for: a eMayo Score, b UCEIS, c panMayo Score, and of colectomy free survival shown
for: d eMayo Score, e UCEIS, f panMayo Score
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The limitation of panMayo Score is that it can be calcu-
lated after a total colonoscopy which is not recommended
in extraordinarily severe cases. The use of IC makes the cal-
culation of panMayo Score slightly complicated, however, it
is necessary for the clear differentiation of active from
inactive disease. On the other hand, the general problem
with every scoring system is that the reproducibility of
endoscopic scores remains suboptimal as a study from Italy
reported; assessment depends on the expertise of the
gastroenterologist [8]. The key of consistent evaluation is
suggested to be a standardized system of description and
endoscopists’ training [29].
Summarizing our data, panMayo Score is a new, disease
extent-related endoscopic score (created with a slight
modification of eMayo) for the assessment of disease
activity in UC, that showed excellent sensitivity and a
good correlation with the parameters of inflammation and
anaemia, Riley, eMayo Score and UCEIS. Nevertheless, it
can be more favourable than the above mentioned endo-
scopic scores because panMayo Score gives additional
information about disease location besides disease activity
with a strong correlation with laboratory parameters of
inflammation and anaemia.
Conclusion
There are many indices available to assess the endoscopic
activity of ulcerative colitis, but all of them have some limi-
tations. The panMayo Score provides additional information
about the extent of the disease besides the disease activity.
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